Research & Development
NeuroSense, NeuraLight partner on biomarkers for ALS
NeuraLight uses proprietary computer vision and learning algorithms to extract coulometric markers from facial videos captured with a webcam. NeuroSense is conducting the phase IIB PARADIGM trial evaluating the efficacy of NeuroSense's lead combination drug candidate, PrimeC, in treating ALS.
July 27, 2022
Arlington Scientific, Brain Chemistry Labs ink collaboration
Only 8% to 10% of ALS cases are genetic, according to Brain Chemistry Labs. In 90% to 92% of cases, environmental risk factors may play a role. BMAA is often present in cyanobacterial blooms in water and is suspected to be the top environmental factor contributing to ALS, the company said.
March 20, 2022
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Page 1 of 1